# Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

> **NCT02242045** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 6 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Indolent Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT02242045
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-01
- **Primary completion:** 2014-12-25
- **Final completion:** 2017-10-17
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242045, "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02242045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*